Methodological approaches to evaluate the impact of FDA drug safety communications.
about
Evaluating the effectiveness of risk minimisation measures: the application of a conceptual framework to Danish real-world dabigatran data.The US Food and Drug Administration's drug safety recommendations and long-acting beta2-agonist dispensing pattern changes in adult asthma patients: 2003-2012.Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice.Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study.Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications.The Impact of FDA Regulatory Activities on Incident Dispensing of LABA-Containing Medication: 2005-2011.Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey.Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis.Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis.
P2860
Q36342841-91AFC3BA-A23C-4435-B3CD-D3FCC0EE2C8BQ37714091-EC1F7C04-F9EE-466D-AB7C-19D77CFFB2EDQ38691294-B858CFDA-6600-4B09-B58E-C5AE1623F550Q38752166-4CAABBE0-83B7-4326-BFF4-48278C8DAED6Q38816487-B8F1949D-D542-4451-88CA-A0F2C50BF97DQ40041139-B4863F0A-73C9-4FB3-91F2-53748DEB68EAQ47161547-CAA457DC-36AF-47CA-A911-1A7CD9B297FCQ47176869-6AF122F2-99F1-495A-8C68-7DA4015541E9Q47653552-FC39ACC3-3D0F-4456-B934-33C1B1A6EAC9Q53403274-D6A9114F-A2E3-4687-98ED-8DB544FE1F63
P2860
Methodological approaches to evaluate the impact of FDA drug safety communications.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Methodological approaches to evaluate the impact of FDA drug safety communications.
@en
Methodological approaches to evaluate the impact of FDA drug safety communications.
@nl
type
label
Methodological approaches to evaluate the impact of FDA drug safety communications.
@en
Methodological approaches to evaluate the impact of FDA drug safety communications.
@nl
prefLabel
Methodological approaches to evaluate the impact of FDA drug safety communications.
@en
Methodological approaches to evaluate the impact of FDA drug safety communications.
@nl
P2093
P2860
P1433
P1476
Methodological approaches to evaluate the impact of FDA drug safety communications.
@en
P2093
Brian M Lappin
Eric G Campbell
Esther H Zhou
Gerald J Dal Pan
Jerry Avorn
John D Seeger
Lisa M Schwartz
Paula Rausch
Sebastian Schneeweiss
Steven Woloshin
P2860
P2888
P304
P356
10.1007/S40264-015-0291-Y
P577
2015-06-01T00:00:00Z